Kymera Therapeutics, Inc.

41.96 USD
+0.12 (+0.29%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Kymera Therapeutics, Inc. stock is up 31.78% since 30 days ago. The next earnings date is May 2, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 February’s closed higher than January. In the last 3 Unusual Options Trades, there were 3 CALLs. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
29 Dec 19:47 21 Jun, 2024 35.00 CALL 100 63
22 Feb 15:27 17 Jan, 2025 55.00 CALL 204 0
22 Feb 20:50 17 Jan, 2025 55.00 CALL 55 0

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases. IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the. treatment of hematologic malignancies and solid tumors.